Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core)

NCT ID: NCT01768325

Last Updated: 2017-03-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate a new EUS-guided biopsy needle (ProCore®) comparing it to conventional EUS-TCB needle (Quick-Core®) in the diagnosis of your suspicious disorder.

This study needle (ProCore®) is a new EUS-guided biopsy needle and has been recently approved by the U.S. Food and Drug Administration (FDA) for use.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective To compare the diagnostic accuracy of new EUS histology needle (19G, ProCore, Cook Medical Inc., Winston-Salem, NC) with the conventional histology needle (19G, Quick-Core, Cook Medical Inc., Winston-Salem, NC)

Secondary Objective To compare

* The number of needle passes requiring to acquire adequate specimen
* Length of core tissue obtained
* Diagnostic contribution of immunohistochemical staining
* Rates of complications

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GIST

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EUS-Guided biopsy needle (ProCore)

Comparison of ProCore core biopsy needle to QuickCore core biopsy needle.Cook Medical core biopsy needle.

* The number of needle passes requiring to acquire adequate specimen
* Length of core tissue obtained
* Diagnostic contribution of immunohistochemical staining
* Rates of complications

Group Type ACTIVE_COMPARATOR

EUS-Guided biopsy needle (ProCore)

Intervention Type DEVICE

* The number of needle passes requiring to acquire adequate specimen were tallied.
* Length of core tissue obtained
* Diagnostic contribution of immunohistochemical staining
* Rates of complications

EUS-TCB needle (Quick-Core)

Comparison of core biopsy needles.

* The number of needle passes requiring to acquire adequate specimen
* Length of core tissue obtained
* Diagnostic contribution of immunohistochemical staining
* Rates of complications

Group Type ACTIVE_COMPARATOR

EUS-TCB needle (QuickCore) standard of care

Intervention Type DEVICE

* The number of needle passes requiring to acquire adequate specimen were tallied.
* Length of core tissue obtained
* Diagnostic contribution of immunohistochemical staining
* Rates of complications

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EUS-TCB needle (QuickCore) standard of care

* The number of needle passes requiring to acquire adequate specimen were tallied.
* Length of core tissue obtained
* Diagnostic contribution of immunohistochemical staining
* Rates of complications

Intervention Type DEVICE

EUS-Guided biopsy needle (ProCore)

* The number of needle passes requiring to acquire adequate specimen were tallied.
* Length of core tissue obtained
* Diagnostic contribution of immunohistochemical staining
* Rates of complications

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Comparison of core biopsy needles. Comparison of core biopsy needles.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Solid tumors ≥ 2 cm in size.

Exclusion Criteria

* Thrombocytopenia
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Indiana University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John M. DeWitt, M.D.

Role: PRINCIPAL_INVESTIGATOR

Indiana University 550 N. University Hospital UH 4100 Indianapolis, IN 46202-5121

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Indiana University Hospital

Indianapolis, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1104-03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Device Study in Healthy Participants
NCT04848402 COMPLETED PHASE1
Suturable DuraGen™ PMCF Study
NCT04923867 COMPLETED
Users Study Of The Caverject Delivery System
NCT01747928 COMPLETED EARLY_PHASE1